Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab + Durvalumab + TACE in Advanced Hepatocellular Carcinoma
2023-510117-26-00Phase 2Completed
- Sponsor
- University College Dublin
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab, durvalumab and doxorubicin in hepatocellular carcinoma (HCC), sponsored by University College Dublin. Primary endpoint: 6-month progression-free survival. Started May 2024; status: completed.
02
Drugs
tiragolumabdurvalumabdoxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-510117-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510117-26-00.